A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
Public ClinicalTrials.gov record NCT04157751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with acute heart failure. Participants are in the study for about 3 months. At the beginning, participants are still in hospital. Later, they visit the hospital about 3 times and get 1 phone call. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. It is used to treat type 2 diabetes. During the study, the doctors check whether participants have additional heart failure events like needing to go to the hospital again because of heart failure. The participants answer questions about how their heart failure affects their life. We then compare the results between the empagliflozin and placebo groups. The doctors also regularly check the general health of the participants.
Study identification
- NCT ID
- NCT04157751
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 530 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2020 (Actual)
- Primary completion
- May 28, 2021 (Actual)
- Completion
- Jun 2, 2021 (Actual)
- Last update posted
- Jul 19, 2022
2020 – 2021
United States locations
- U.S. sites
- 30
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of California Irvine | Orange | California | 92865 | — |
| The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | 90502 | — |
| Cardiology Associates Research Co. | Daytona Beach | Florida | 32117 | — |
| University of Florida Health Jacksonville | Jacksonville | Florida | 32209 | — |
| Grady Memorial Hospital | Atlanta | Georgia | 30303 | — |
| Methodist Medical Center | Peoria | Illinois | 61603 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| United Hospital | Saint Paul | Minnesota | 55102 | — |
| University Of Mississippi Medical Center | Jackson | Mississippi | 39216-4505 | — |
| Saint Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Cardiovascular Associates of the Delaware Valley | Elmer | New Jersey | 08318 | — |
| Jefferson Washington Township Hospital | Washington Township | New Jersey | 08080 | — |
| Erie County Medical Center | Buffalo | New York | 14215 | — |
| The DeMatteis Center for Cardiac Research and Education | Greenvale | New York | 11548 | — |
| Stony Brook Medicine | Stony Brook | New York | 11794 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| North Carolina Heart and Vascular | Raleigh | North Carolina | 27607 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| South Oklahoma Heart Research Group | Oklahoma City | Oklahoma | 73135 | — |
| Ralph H. Johnson VA Medical Center | Charleston | South Carolina | 29401 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Pharmatex Research | Amarillo | Texas | 79109 | — |
| Center for Advanced Cardiac Care - Heart Failure Clinic | Plano | Texas | 75093 | — |
| Inova Fairfax Medical Campus | Falls Church | Virginia | 22042 | — |
| Sentara Norfolk General Hospital | Norfolk | Virginia | 23507 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04157751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2022 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04157751 live on ClinicalTrials.gov.